Literature DB >> 1176586

Altered blood androgens in elderly men with prostate hyperplasia.

R Horton, P Hsieh, J Barberia, L Pages, M Cosgrove.   

Abstract

Plasma testosterone (T) and dihydrotestosterone (DHT) were measured in the plasma of otherwise healthy men ages 60-90 who had prostate hyperplasia. The androgens were measured by specific radioimmunoassays using paper and celite column chromatography. In the elderly subjects, plasma T was 466+/-35 (SE) ng per 100 ml which is reduced (p less than 0.05) as compared with values from younger men. In contrast, DHT levels were elevated when compared with values from men ages 20-39, 89 (53-152) versus 49 (33-74) 95% confidence ng per 100 ml. Analysis of data by the Mann Whitney U test demonstrates that the groups are different (p less than 0.001). These studies indicate that DHT levels and T/DHT ratios are altered in unstressed elderly men with BPH. Further study is necessary to delineate the source of DHT and whether these altered androgen levels are the cause of prostate hypertrophy or an unrelated effect of aging.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1176586     DOI: 10.1210/jcem-41-4-793

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Acute resistance exercise does not change the hormonal response to sublingual androstenediol intake.

Authors:  Gregory A Brown; Drew McKenzie
Journal:  Eur J Appl Physiol       Date:  2006-04-25       Impact factor: 3.078

Review 2.  Landmarks in BPH--from aetiology to medical and surgical management.

Authors:  Arman Kahokehr; Peter J Gilling
Journal:  Nat Rev Urol       Date:  2014-01-21       Impact factor: 14.432

3.  Advanced carcinoma of the prostate- does the pre-treatment Leydig cell function determine the response to orchidectomy?

Authors:  A L Houghton; H S Jacobs
Journal:  Postgrad Med J       Date:  1978-04       Impact factor: 2.401

4.  Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Authors:  Kouji Izumi; Lei Li; Chawnshang Chang
Journal:  Clin Investig (Lond)       Date:  2014-10-01

5.  Alteration in the metabolism of dihydrotestosterone in elderly men with prostate hyperplasia.

Authors:  I Morimoto; A Edmiston; R Horton
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

6.  Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men.

Authors:  E Ortega; E Ruiz; M C Mendoza; A Martin-Andres; C Osorio
Journal:  Experientia       Date:  1979-06-15

7.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Alan R Kristal; Jeannette M Schenk; YoonJu Song; Kathryn B Arnold; Marian L Neuhouser; Phyllis J Goodman; Daniel W Lin; Frank Z Stanczyk; Ian M Thompson
Journal:  Am J Epidemiol       Date:  2008-10-21       Impact factor: 4.897

Review 8.  Androgen receptor roles in the development of benign prostate hyperplasia.

Authors:  Kouji Izumi; Atsushi Mizokami; Wen-Jye Lin; Kuo-Pao Lai; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-04-06       Impact factor: 4.307

9.  5-Fluorouracil (5-Fu) in the treatment of prostatic hyperplasia.

Authors:  X Y Wei; X M Zhou
Journal:  Urol Res       Date:  1987

10.  Studies on the role of the sex-hormone-binding globulin (SHBG) in prostatic gland hypertrophy in men. II. In vitro research.

Authors:  A Pachman
Journal:  Int Urol Nephrol       Date:  1984       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.